1/4

2/4 Liver Enzymes Information 3/4
Welcome to my compendium website on Liver Enzymes. This site will give you a lot of information  helpful to learn about your liver.  My liver is not doing what it should.  I am on my 2nd round of a bout with cancer. It started as a tumor in my parotid gland. ( Read details at   www.IamFightingCancer.com )

6 months ago I developed a significant cough. Finally after a couple of months it was determined that my Parotid Gland tumor that was gone had metastiszed  showing up in my left lung. After a chemo scheduled every 3 weeks  it was re-scheduled to  a weekly infusion to lessen the side effects.

One of the side effects was depression for which I was prescribed a prescription of the generic sertraline, 50 mg. which is better known as Zoloft. It was determined that my blood tests showed that my liver enzymes were 10 times what they should be. WOW.  One of the possible causes was the DOCETAIL chemotherapy.  Dr. G. stopped the chemo but continued on with the herceptin for HER2 Another blood test was taken. Now the bad count in the blood had not improved but had gotten worse than before.  YUK.  WHAT IS CAUSING MY LIVER TO PRODUCE TOO MANY ENZYMES.

The new experiment would be to cut off the only pill I  am taking which would be the Zoloft or Sertraline, 50 mg.  A week later blood test showed that the enzyme count was down but the count was still bad enough to prevent any type of serving of the standard chemo. Dr. G felt it was the Zoloft because cutting it down improve the liver function. Today1-25-07 I will take the Herceptin infusion and not any chemo for 2 more weeks to see if the blood will return to more reasonable level. As I research more about the causes of liver damage  for my own use,  I will document them below to better enhance your personal awareness of the problem. 

I will research Zoloft further to see what sides effects the manufacture indicates could happen.  Do you have any experience with Zoloft?  If so please e-mail me
Click: E-mail me   I will post your comments on this website.

You can find this site again  by typing in the  Google search engine  the unique word " 1semyznEreviL "  which is  OR "  LiverEnzymes1 " backwards.

 

1/3  

Directory of Video Sites
Blue Box 1
Scan Below

Click Brian Nelson's www.PartyTentCity.com for party tents, canopies and awnings. Today's Sale 26'x40' Tarp.   Silver. Regular price is $104.00. With this ad it is on sale for only $88.00. Shipping is $15. No charge for shipping if tarp is picked up at  31 Gessner Rd.  in Houston, TX  77024  Use PayPal to Brian@NelsonIdeas.com or Call Brian 713-467-3025.  
Blue Box 1 Contact Brian at 31 Gessner Rd. Houston, TX  77024 Tel. 713-467-3025 Cell 713-927-4479 Click: E-mail me 
www.IamFightingCancer.com   Bookmark this page now!   Anything Internet   
http://www.NelsonIdeas.com/Directory-All-Websites/Alphabetical.html

  09/24/2009 02:35 PM -0500

 

1

2/3

2

 Directory of Sites
Blue Box 2  Brian Nelson

 Do you need a party tent of white or silver tarp? Go to www.PartyTentCity.com or to see all my links go to:  http://www.PartyTentCity.com/PTC/Websites.html

Today's  special sale: Business is slow. Call me right now while this include page is up and get a 23% discount off any www.PartyTentCity.com  order.  No charge for shipping if picked up at  31 Gessner Rd.  in Houston, TX  77024 Use PayPal to Brian@NelsonIdeas.com or Call Brian 713-467-3025. http://www.NelsonIdeas.com/Directory-All-Websites/Alphabetical.html
Blue Box 2  Bookmark this page now!  
Contact Brian at 31 Gessner Rd. Houston, TX  77024 Tel. 713-467-3025 Cell 713-927-4479
Click: E-mail me 
www.IamFightingCancer.com   
 

-----------------

3/3  

 

If  after you scan to the bottom of this very large webpage  and can't find the information you are looking for try another Google search here.
Contact information for this Website:
 
Brian Nelson
Webpage Marketing Consultant 

 31 Gessner Rd. Houston, TX 77024
08/29/2009 05:05 PM -0500
713-467-3025  Fax 713-467-3192  
Click: E-mail me

You are at: http://www.NewMedicalDirectories.com/Liver-Enzymes/Information.html    ud 08/29/2009 05:05 PM -0500  Bookmark this page now!

 

Liver

Liver
Liver of a sheep: (1) right lobe, (2) left lobe, (3) caudate lobe, (4) quadrate lobe, (5) hepatic artery and portal vein, (6) hepatic lymph nodes, (7) gall bladder.
Gray's subject #250 1188
Artery hepatic artery
Vein hepatic vein, portal vein
Nerve celiac ganglia, vagus[1]
Precursor foregut
MeSH Liver

The liver is an organ in some animals, including mammals (and therefore humans), birds, and reptiles. It plays a major role in metabolism and has a number of functions in the body including glycogen storage, plasma protein synthesis, and drug detoxification. This organ also is the largest gland in the human body. It produces bile, which is important in digestion. It performs and regulates a wide variety of high-volume biochemical reactions requiring specialized tissues. Medical terms related to the liver often start in hepato- or hepatic from the Greek word for liver, hepar.

Contents

[hide]

  Anatomy

Superior surface

Superior surface

Inferior surface

Inferior surface

Posterior and inferior surfaces

Posterior and inferior surfaces

The adult human liver normally weighs between 1.3 - 3.0 kilograms, and it is a soft, pinkish-brown "boomerang shaped" organ. It is the second largest organ (the largest organ being the skin) and the largest gland within the human body.

It is located on the right side of the upper abdomen body diaphragm. The liver lies on the right of the stomach and makes a kind of bed for the gallbladder (which stores bile).

  Flow of blood

The splenic vein, joining with the superior mesenteric vein to form the portal vein, brings venous blood from the spleen, pancreas, small intestine, and large intestine, so that the liver can process the nutrients and byproducts of food digestion.

The hepatic veins drain directly into the inferior vena cava.

The hepatic artery is generally a branch from the celiac trunk, although occasionally some or all of the blood can be from other branches such as the superior mesenteric artery.

Approximately ⅔ of the blood flow to the liver is from the portal venous system, and ⅓ is from the hepatic artery.

  Flow of bile

The bile produced in the liver is collected in bile canaliculi, which merge to form bile ducts.

These eventually drain into the right and left hepatic ducts, which in turn merge to form the common hepatic duct. The cystic duct (from the gallbladder) joins with the common hepatic duct to form the common bile duct.

Bile can either drain directly into the duodenum via the common bile duct or be temporarily stored in the gallbladder via the cystic duct. The common bile duct and the pancreatic duct enter the duodenum together at the ampulla of Vater.

The branchings of the bile ducts resemble those of a tree, and indeed the term "biliary tree" is commonly used in this setting.

  Regeneration

The liver is among the few internal human organs capable of natural regeneration of lost tissue; as little as 25% of remaining liver can regenerate into a whole liver again.

This is predominantly due to the hepatocytes acting as unipotential stem cells (i.e. a single hepatocyte can divide into two hepatocyte daughter cells). There is also some evidence of bipotential stem cells, called oval cells, which can differentiate into either hepatocytes or cholangiocytes (cells that line the bile ducts).

  Peritoneal ligaments

Apart from a patch where it connects to the diaphragm, the liver is covered entirely by visceral peritoneum, a thin, double-layered membrane that reduces friction against other organs. The peritoneum folds back on itself to form the falciform ligament and the right and left triangular ligaments.

These "ligaments" are in no way related to the true anatomic ligaments in joints, and have essentially no functional importance, but they are easily recognizable surface landmarks.

  Lobes

Traditional gross anatomy divided the liver into four lobes based on surface features.

The falciform ligament is visible on the front (anterior side) of the liver. This divides the liver into a left anatomical lobe, and a right anatomical lobe.

If the liver is flipped over, to look at it from behind (the visceral surface), there are two additional lobes between the right and left. These are the caudate lobe (the more superior), and below this the quadrate lobe.

From behind, the lobes are divided up by the ligamentum venosum and ligamentum teres (anything left of these is the left lobe), the transverse fissure (or porta hepatis) divides the caudate from the quadrate lobe, and the right sagittal fossa, which the inferior vena cava runs over, separates these two lobes from the right lobe.

  Modern (Functional) anatomy

For purposes such as advanced liver surgery, it is crucial to understand the fundamental importance of the liver on the blood supply and biliary drainage system. The central area where the common bile duct, portal vein, and hepatic artery enter the liver is the hilum or "porta hepatis". The duct, vein, and artery divide into left and right branches, and the portions of the liver supplied by these branches constitute the functional left and right lobes.

The functional lobes are separated by a plane joining the gallbladder fossa to the inferior vena cava. This separates the liver into the true right and left lobes. The middle hepatic vein also demarcates the true right and left lobes. The right lobe is further divided into an anterior and posterior segment by the right hepatic vein. The left lobe is divided into the medial and lateral segments by the left hepatic vein. The fissure for the ligamentum teres (the ligamentum teres becomes the falciform ligament) also separates the medial and lateral segmants. The medial segment is what used to be called the quadrate lobe. In the widely used Couinaud or "French" system, the functional lobes are further divided into a total of eight subsegments based on a transverse plane through the bifurcation of the main portal vein. The caudate lobe is a separate structure which receives blood flow from both the right- and left-sided vascular branches.[2][3] The subsegments corresponding to the anatomical lobes are as follows:

Segment* Couinaud segments
Caudate 1
Lateral 2, 3
Medial 4a, 4b
Right 5, 6, 7, 8
  • or lobe in the Caudate's case.

Each number in the list corresponds to one in the table.

  1. Caudate
  2. Superior subsegment of the lateral segment
  3. Inferior subsegment of the lateral segment
  4.  
    1. Superior subsegment of the medial segment
    2. Inferior subsegment of the medial segment
  5. Inferior subsegment of the anterior segment
  6. Inferior subsegment of the posterior segment
  7. Superior subsegment of the posterior segment
  8. Superior subsegment of the anterior segment

  Physiology

The various functions of the liver are carried out by the liver cells or hepatocytes.

Currently, there is no artificial organ or device capable of emulating all the functions of the liver. Some functions can be emulated by liver dialysis, an experimental treatment for liver failure.

Diseases of the liver

Many diseases of the liver are accompanied by jaundice caused by increased levels of bilirubin in the system. The bilirubin results from the breakup of the hemoglobin of dead red blood cells; normally, the liver removes bilirubin from the blood and excretes it through bile.

There are also many pediatric liver disease, including biliary atresia, alpha-1 antitrypsin deficiency, alagille syndrome, and progressive familial intrahepatic cholestasis, to name but a few.

A number of liver function tests are available to test the proper function of the liver. These test for the presence of enzymes in blood that are normally most abundant in liver tissue, metabolites or products.

Liver transplantation

Human liver transplant was first performed by Thomas Starzl in USA and Roy Calne in England in 1963 and 1965 respectively.

Liver transplantation is the only option for those with irreversible liver failure. Most transplants are done for chronic liver diseases leading to cirrhosis, such as chronic hepatitis C, alcoholism, autoimmune hepatitis, and many others. Less commonly, liver transplantation is done for fulminant hepatic failure, in which liver failure occurs over days to weeks.

Liver allografts for transplant usually come from non-living donors who have died from fatal brain injury. Living donor liver transplantation is a technique in which a portion of a living person's liver is removed and used to replace the entire liver of the recipient. This was first performed in 1989 for pediatric liver transplantation. Only 20% of an adult's liver (Couinaud segments 2 and 3) is needed to serve as a liver allograft for an infant or small child.

More recently, adult-to-adult liver transplantation has been done using the donor's right hepatic lobe which amounts to 60% of the liver. Due to the ability of the liver to regenerate, both the donor and recipient end up with normal liver function if all goes well. This procedure is more controversial as it entails performing a much larger operation on the donor, and indeed there have been at least 2 donor deaths out of the first several hundred cases. A recent publication has addressed the problem of donor mortality, and at least 14 cases have been found.[4] The risk of postoperative complications (and death) is far greater in right sided hepatectomy than left sided operations

Development

The liver develops as an endodermal outpocketing of the foregut called the hepatic diverticulum. Its initial blood supply is primarily from the vitelline veins that drain blood from the yolk sac. The superior part of the hepatic diverticulum gives rise to the hepatocytes and bile ducts, while the inferior part becomes the gallbladder and its associated cystic duct.

Fetal blood supply

In the growing fetus, a major source of blood to the liver is the umbilical vein which supplies nutrients to the growing fetus. The umbilical vein enters the abdomen at the umbilicus, and passes upward along the free margin of the falciform ligament of the liver to the inferior surface of the liver. There it joins with the left branch of the portal vein. The ductus venosus carries blood from the left portal vein to the left hepatic vein and thence to the inferior vena cava, allowing placental blood to bypass the liver.

In the fetus, the liver is developing throughout normal gestation, and does not perform the normal filtration of the infant liver. The liver does not perform digestive processes because the fetus does not consume meals directly, but receives nourishment from the mother via the placenta. The fetal liver releases some blood stem cells that migrate to the fetal thymus, so initially the lymphocytes, called T-cells, are created from fetal liver stem cells. Once the fetus is delivered, the formation of blood stem cells in infants shifts to the red bone marrow.

After birth, the umbilical vein and ductus venosus are completely obliterated two to five days postpartum; the former becomes the ligamentum teres and the latter becomes the ligamentum venosum. In the disease state of cirrhosis and portal hypertension, the umbilical vein can open up again.

 

Liver function tests

Liver function tests (LFTs or LFs), which include liver enzymes, are groups of clinical biochemistry laboratory blood assays designed to give information about the state of a patient's liver. Most liver diseases cause only mild symptoms initially, while it is vital that these diseases be detected early. Hepatic involvement in some diseases can be of crucial importance. This testing is performed by a Medical technologist on a patient's serum or plasma which is collected by a phlebotomist.

Contents

[hide]

  Standard liver panel

  Total Protein (TP)

The liver produces most of the plasma proteins in the body making a measure of the amount of protein in the blood useful. Reference range (60-80 g/L).

  Albumin (Alb)

Albumin is a protein made specifically by the liver, and can be measured cheaply and easily. It is the main constituent of total protein; the remaining fraction is called globulin (including e.g. the immunoglobulins). Albumin levels are decreased in chronic liver disease, such as cirrhosis. It is also decreased in nephrotic syndrome, where it is lost through the urine. Poor nutrition or states of protein catabolism may also lead to hypoalbuminaemia. The half-life of albumin is approximately 20 days. Albumin is not considered to be an especially useful marker of liver synthetic function, coagulation factors (see below) are much more sensitive. The reference range is 30-50 g/L. (3.0-5.0 g/dL)

  Alanine transaminase (ALT)

Alanine transaminase (ALT), also called Serum Glutamic Pyruvic Transaminase (SGPT) or Alanine aminotransferase (ALAT) is an enzyme present in hepatocytes (liver cells). When a cell is damaged, it leaks this enzyme into the blood, where it is measured. ALT rises dramatically in acute liver damage, such as viral hepatitis or paracetamol (acetaminophen) overdose. Elevations are often measured in multiples of the upper limit of normal (ULN). The reference range is 15-45 U/L in most laboratories.

  Aspartate transaminase (AST)

Aspartate transaminase (AST) also called Serum Glutamic Oxaloacetic Transaminase (SGOT) or aspartate aminotransferase (ASAT) is similar to ALT in that it is another enzyme associated with liver parenchymal cells. It is raised in acute liver damage, but is also present in red cells, and cardiac and skeletal muscle and is therefore not specific to the liver. The ratio of AST to ALT is sometimes useful in differentiating between causes of liver damage:

In resource-poor settings, the AST is more frequently available than the ALT, because it is a cheaper assay.

  Alkaline phosphatase (ALP)

Alkaline phosphatase (ALP) is an enzyme in the cells lining the biliary ducts of the liver. ALP levels in plasma will rise with large bile duct obstruction, intrahepatic cholestasis or infiltrative diseases of the liver. ALP is also present in bone and placental tissue, so it is higher in growing children (as their bones are being remodelled). The reference range is usually 30-120 U/L.

  Total bilirubin (TBIL)

Bilirubin is a breakdown product of heme (a part of haemoglobin in red blood cells). The liver is responsible for clearing the blood of bilirubin. It does this by the following mechanism: bilirubin is taken up into hepatocytes, conjugated (modified to make it water-soluble), and secreted into the bile, which is excreted into the intestine.

Liver function tests typically measure Total bilirubin (TBIL) and Direct bilirubin (a.k.a. conjugated bilirubin, CB). Indirect bilirubin (a.k.a. unconjugated bilirubin, UCB) is obtained by subtracting direct bilirubin from total bilirubin.

Increased total bilirubin causes jaundice, and can signal a number of problems:

1. Increased bilirubin production. This can be due to a number of causes, including hemolytic anemias and internal hemorrhage.

2. Problems with the liver, which are reflected as deficiencies in bilirubin metabolism (e.g. reduced hepatocyte uptake, impaired conjugation of bilirubin, and reduced hepatocyte secretion of bilirubin). Some examples would be cirrhosis and viral hepatitis.

3. Obstruction of the bile ducts, reflected as deficiencies in bilirubin excretion. (Obstruction can be located either within the liver or outside the liver.)

The diagnosis is narrowed down further by looking at the levels of direct bilirubin. If direct (i.e. conjugated) bilirubin is normal, then the problem is an excess of unconjugated bilirubin, and the location of the problem is upstream of bilirubin excretion. Anemia, viral hepatitis, or cirrhosis can be suspected. If direct bilirubin is elevated, then the liver is conjugating bilirubin normally, but is not able to excrete it. Bile duct obstruction by gallstones or cancer should be suspected.

  :

 

  Gamma glutamyl transpeptidase (GGT)

Although reasonably specific to the liver and a more sensitive marker for cholestatic damage than ALP, Gamma glutamyl transpeptidase (GGT) may be elevated with even minor, sub-clinical levels of liver dysfunction. It can also be helpful in identifying the cause of an isolated elevation in ALP. GGT is raised in alcohol toxicity (acute and chronic).

  5' nucleotidase (5'NTD)

5'NTD is another test specific for cholestasis or damage to the intra or extrahepatic biliary system, and in some laboratories, is used as a substitute for GGT for ascertaining whether an elevated ALP is of biliary or extra-biliary origin.

  Coagulation tests (e.g. INR)

The liver is responsible for the production of coagulation factors. The international normalized ratio (INR) measures the speed of a particular pathway of coagulation, comparing it to normal. If the INR is increased, it means it is taking longer than usual for blood to clot. The INR will only be increased if the liver is so damaged that synthesis of vitamin K-dependent coagulation factors has been impaired: it is not a sensitive measure of liver function.

It is very important to normalize the INR before operating on people with liver problems (usually by transfusion with blood plasma containing the deficient factors) as they could bleed excessively.

  Serum glucose (BG, Glu)

The liver's ability to produce glucose (gluconeogenesis) is usually the last function to be lost in the setting of fulminant liver failure.

 

Liver function tests

From Wikipedia, the free encyclopedia

 
Jump to: navigation, search

Liver function tests (LFTs or LFs), which include liver enzymes, are groups of clinical biochemistry laboratory blood assays designed to give information about the state of a patient's liver. Most liver diseases cause only mild symptoms initially, while it is vital that these diseases be detected early. Hepatic involvement in some diseases can be of crucial importance. This testing is performed by a Medical technologist on a patient's serum or plasma which is collected by a phlebotomist.

Contents

[hide]

  Standard liver panel

 

  Total Protein (TP)

The liver produces most of the plasma proteins in the body making a measure of the amount of protein in the blood useful. Reference range (60-80 g/L).

 

  Albumin (Alb)

Albumin is a protein made specifically by the liver, and can be measured cheaply and easily. It is the main constituent of total protein; the remaining fraction is called globulin (including e.g. the immunoglobulins). Albumin levels are decreased in chronic liver disease, such as cirrhosis. It is also decreased in nephrotic syndrome, where it is lost through the urine. Poor nutrition or states of protein catabolism may also lead to hypoalbuminaemia. The half-life of albumin is approximately 20 days. Albumin is not considered to be an especially useful marker of liver synthetic function, coagulation factors (see below) are much more sensitive. The reference range is 30-50 g/L. (3.0-5.0 g/dL)

 

  Alanine transaminase (ALT)

Alanine transaminase (ALT), also called Serum Glutamic Pyruvic Transaminase (SGPT) or Alanine aminotransferase (ALAT) is an enzyme present in hepatocytes (liver cells). When a cell is damaged, it leaks this enzyme into the blood, where it is measured. ALT rises dramatically in acute liver damage, such as viral hepatitis or paracetamol (acetaminophen) overdose. Elevations are often measured in multiples of the upper limit of normal (ULN). The reference range is 15-45 U/L in most laboratories.

 

  Aspartate transaminase (AST)

Aspartate transaminase (AST) also called Serum Glutamic Oxaloacetic Transaminase (SGOT) or aspartate aminotransferase (ASAT) is similar to ALT in that it is another enzyme associated with liver parenchymal cells. It is raised in acute liver damage, but is also present in red cells, and cardiac and skeletal muscle and is therefore not specific to the liver. The ratio of AST to ALT is sometimes useful in differentiating between causes of liver damage:

In resource-poor settings, the AST is more frequently available than the ALT, because it is a cheaper assay.

 

  Alkaline phosphatase (ALP)

Alkaline phosphatase (ALP) is an enzyme in the cells lining the biliary ducts of the liver. ALP levels in plasma will rise with large bile duct obstruction, intrahepatic cholestasis or infiltrative diseases of the liver. ALP is also present in bone and placental tissue, so it is higher in growing children (as their bones are being remodelled). The reference range is usually 30-120 U/L.

 

  Total bilirubin (TBIL)

Bilirubin is a breakdown product of heme (a part of haemoglobin in red blood cells). The liver is responsible for clearing the blood of bilirubin. It does this by the following mechanism: bilirubin is taken up into hepatocytes, conjugated (modified to make it water-soluble), and secreted into the bile, which is excreted into the intestine.

Liver function tests typically measure Total bilirubin (TBIL) and Direct bilirubin (a.k.a. conjugated bilirubin, CB). Indirect bilirubin (a.k.a. unconjugated bilirubin, UCB) is obtained by subtracting direct bilirubin from total bilirubin.

Increased total bilirubin causes jaundice, and can signal a number of problems:

1. Increased bilirubin production. This can be due to a number of causes, including hemolytic anemias and internal hemorrhage.

2. Problems with the liver, which are reflected as deficiencies in bilirubin metabolism (e.g. reduced hepatocyte uptake, impaired conjugation of bilirubin, and reduced hepatocyte secretion of bilirubin). Some examples would be cirrhosis and viral hepatitis.

3. Obstruction of the bile ducts, reflected as deficiencies in bilirubin excretion. (Obstruction can be located either within the liver or outside the liver.)

The diagnosis is narrowed down further by looking at the levels of direct bilirubin. If direct (i.e. conjugated) bilirubin is normal, then the problem is an excess of unconjugated bilirubin, and the location of the problem is upstream of bilirubin excretion. Anemia, viral hepatitis, or cirrhosis can be suspected. If direct bilirubin is elevated, then the liver is conjugating bilirubin normally, but is not able to excrete it. Bile duct obstruction by gallstones or cancer should be suspected.

 

  Other tests commonly requested alongside LFTs:

 

  Gamma glutamyl transpeptidase (GGT)

Although reasonably specific to the liver and a more sensitive marker for cholestatic damage than ALP, Gamma glutamyl transpeptidase (GGT) may be elevated with even minor, sub-clinical levels of liver dysfunction. It can also be helpful in identifying the cause of an isolated elevation in ALP. GGT is raised in alcohol toxicity (acute and chronic).

 

  5' nucleotidase (5'NTD)

5'NTD is another test specific for cholestasis or damage to the intra or extrahepatic biliary system, and in some laboratories, is used as a substitute for GGT for ascertaining whether an elevated ALP is of biliary or extra-biliary origin.

 

  Coagulation tests (e.g. INR)

The liver is responsible for the production of coagulation factors. The international normalized ratio (INR) measures the speed of a particular pathway of coagulation, comparing it to normal. If the INR is increased, it means it is taking longer than usual for blood to clot. The INR will only be increased if the liver is so damaged that synthesis of vitamin K-dependent coagulation factors has been impaired: it is not a sensitive measure of liver function.

It is very important to normalize the INR before operating on people with liver problems (usually by transfusion with blood plasma containing the deficient factors) as they could bleed excessively.

 

  Serum glucose (BG, Glu)

The liver's ability to produce glucose (gluconeogenesis) is usually the last function to be lost in the setting of fulminant liver failure.

 

HELLP syndrome

From Wikipedia, the free encyclopedia

 
Jump to: navigation, search
HELLP syndrome
Classifications and external resources
ICD-10 O14.1
ICD-9 Not assigned
DiseasesDB 30805

HELLP syndrome is a life-threatening complication of pre-eclampsia. Both conditions occur during the latter stages of pregnancy, or sometimes after childbirth.

HELLP is an abbreviation of the main findings:

Contents

[hide]

  Signs and symptoms

Often, a patient who develops HELLP syndrome has already been followed up for pregnancy-induced hypertension (gestational hypertension), or is suspected to develop pre-eclampsia (high blood pressure and proteinuria). Up to 8% of all cases present after delivery.

There is gradual but marked onset of headaches (30%), blurred vision, malaise (90%), nausea/vomiting (30%), "band pain" around the upper abdomen (65%) and tingling in the extremities. Oedema may occur but its absence does not exclude HELLP syndrome. Arterial hypertension is a diagnostic requirement, but may be mild. Rupture of the liver capsule and a resultant hematoma may occur. If the patient gets a seizure or coma, the condition has progressed into full-blown eclampsia.

Patients who present symptoms of HELLP can be misdiagnosed in the early stages, increasing the risk of liver failure and morbidity (Padden, 1999).

 

  Diagnosis

In a patient with possible HELLP syndrome, a batch of blood tests is performed: a full blood count, liver enzymes, renal function and electrolytes and coagulation studies. Often, fibrin degradation products (FDPs) are determined, which can be elevated. Lactate dehydrogenase is a marker of hemolysis and is elevated (>600 U/liter). Proteinuria is present but can be mild.

 

  Classification

The platelet count has been found to be moderately predictive of severity: under 50 million/L is class I (severe), between 50 and 100 is class II (moderately severe) and >100 is class III (mild). This system is termed the Mississippi classification (Martin et al 1990).

 

  Pathophysiology

The exact cause of HELLP is unknown, but general activation of the coagulation cascade is considered the main underlying problem. Fibrin forms crosslinked networks in the small blood vessels. This leads to a microangiopathic hemolytic anemia: the mesh causes destruction of red blood cells as if they were being forced through a strainer. Additionally, platelets are consumed. As the liver appears to be the main site of this process, downstream liver cells suffer ischemia, leading to periportal necrosis. Other organs can be similarly affected. HELLP syndrome leads to a variant form of disseminated intravascular coagulation (DIC), leading to paradoxical bleeding, which can make emergency surgery a serious challenge.

 

  Treatment

The only effective treatment is delivery of the baby, preferably by cesarean section. Several medications have been investigated for the treatment of HELLP syndrome, but evidence is conflicting as to whether magnesium sulfate decreases the risk of seizures and progress to eclampsia. The DIC is treated with fresh frozen plasma to replenish the coagulation proteins, and the anemia may require blood transfusion. In mild cases, corticosteroids and antihypertensives (labetalol, hydralazine, nifedipine) may be sufficient. Intravenous fluids are generally required.

 

  Epidemiology

Its incidence is reported as 0.2-0.6% of all pregnancies. Of women with (pre)eclampsia, 4-12% also develop signs of a "superimposed" HELLP syndrome. Mortality is 7-35% and perinatal mortality of the child may be up to 40%. HELLP usually begins after the third trimester, and usually in Caucasian women over the age of 25. (Padden, 1999.) Rarely, cases have been reported as early as 23 weeks gestation.

 

  History

HELLP syndrome was identified as a distinct clinical entity (as opposed to severe preeclampsia) by Dr Louis Weinstein in 1982.

 
HELLP syndrome
HELLP syndrome
Classifications and external resources
ICD-10 O14.1
ICD-9 Not assigned
DiseasesDB 30805

HELLP syndrome is a life-threatening complication of pre-eclampsia. Both conditions occur during the latter stages of pregnancy, or sometimes after childbirth.

HELLP is an abbreviation of the main findings:

 

Signs and symptoms

Often, a patient who develops HELLP syndrome has already been followed up for pregnancy-induced hypertension (gestational hypertension), or is suspected to develop pre-eclampsia (high blood pressure and proteinuria). Up to 8% of all cases present after delivery.

There is gradual but marked onset of headaches (30%), blurred vision, malaise (90%), nausea/vomiting (30%), "band pain" around the upper abdomen (65%) and tingling in the extremities. Oedema may occur but its absence does not exclude HELLP syndrome. Arterial hypertension is a diagnostic requirement, but may be mild. Rupture of the liver capsule and a resultant hematoma may occur. If the patient gets a seizure or coma, the condition has progressed into full-blown eclampsia.

Patients who present symptoms of HELLP can be misdiagnosed in the early stages, increasing the risk of liver failure and morbidity (Padden, 1999).

 

Diagnosis

In a patient with possible HELLP syndrome, a batch of blood tests is performed: a full blood count, liver enzymes, renal function and electrolytes and coagulation studies. Often, fibrin degradation products (FDPs) are determined, which can be elevated. Lactate dehydrogenase is a marker of hemolysis and is elevated (>600 U/liter). Proteinuria is present but can be mild.

 

Classification

The platelet count has been found to be moderately predictive of severity: under 50 million/L is class I (severe), between 50 and 100 is class II (moderately severe) and >100 is class III (mild). This system is termed the Mississippi classification (Martin et al 1990).

 

Pathophysiology

The exact cause of HELLP is unknown, but general activation of the coagulation cascade is considered the main underlying problem. Fibrin forms crosslinked networks in the small blood vessels. This leads to a microangiopathic hemolytic anemia: the mesh causes destruction of red blood cells as if they were being forced through a strainer. Additionally, platelets are consumed. As the liver appears to be the main site of this process, downstream liver cells suffer ischemia, leading to periportal necrosis. Other organs can be similarly affected. HELLP syndrome leads to a variant form of disseminated intravascular coagulation (DIC), leading to paradoxical bleeding, which can make emergency surgery a serious challenge.

 

Treatment

The only effective treatment is delivery of the baby, preferably by cesarean section. Several medications have been investigated for the treatment of HELLP syndrome, but evidence is conflicting as to whether magnesium sulfate decreases the risk of seizures and progress to eclampsia. The DIC is treated with fresh frozen plasma to replenish the coagulation proteins, and the anemia may require blood transfusion. In mild cases, corticosteroids and antihypertensives (labetalol, hydralazine, nifedipine) may be sufficient. Intravenous fluids are generally required.

 

Epidemiology

Its incidence is reported as 0.2-0.6% of all pregnancies. Of women with (pre)eclampsia, 4-12% also develop signs of a "superimposed" HELLP syndrome. Mortality is 7-35% and perinatal mortality of the child may be up to 40%. HELLP usually begins after the third trimester, and usually in Caucasian women over the age of 25. (Padden, 1999.) Rarely, cases have been reported as early as 23 weeks gestation.

 

History

HELLP syndrome was identified as a distinct clinical entity (as opposed to severe preeclampsia) by Dr Louis Weinstein in 1982.

 

 
Liver function tests
Liver function tests (LFTs or LFs), which include liver enzymes, are groups of clinical biochemistry laboratory blood assays designed to give information about the state of a patient's liver. Most liver diseases cause only mild symptoms initially, while it is vital that these diseases be detected early. Hepatic involvement in some diseases can be of crucial importance. This testing is performed by a Medical technologist on a patient's serum or plasma which is collected by a phlebotomist.

 

Standard liver panel

 

Total Protein (TP)

The liver produces most of the plasma proteins in the body making a measure of the amount of protein in the blood useful. Reference range (60-80 g/L).

 

Albumin (Alb)

Albumin is a protein made specifically by the liver, and can be measured cheaply and easily. It is the main constituent of total protein; the remaining fraction is called globulin (including e.g. the immunoglobulins). Albumin levels are decreased in chronic liver disease, such as cirrhosis. It is also decreased in nephrotic syndrome, where it is lost through the urine. Poor nutrition or states of protein catabolism may also lead to hypoalbuminaemia. The half-life of albumin is approximately 20 days. Albumin is not considered to be an especially useful marker of liver synthetic function, coagulation factors (see below) are much more sensitive. The reference range is 30-50 g/L. (3.0-5.0 g/dL)

 

Alanine transaminase (ALT)

Alanine transaminase (ALT), also called Serum Glutamic Pyruvic Transaminase (SGPT) or Alanine aminotransferrase (ALAT) is an enzyme present in hepatocytes (liver cells). When a cell is damaged, it leaks this enzyme into the blood, where it is measured. ALT rises dramatically in acute liver damage, such as viral hepatitis or paracetamol (acetaminophen) overdose. Elevations are often measured in multiples of the upper limit of normal (ULN). The reference range is 15-45 U/L in most laboratories.

 

Aspartate transaminase (AST)

Aspartate transaminase (AST) also called Serum Glutamic Oxaloacetic Transaminase (SGOT) or aspartate aminotransferase (ASAT) is similar to ALT in that it is another enzyme associated with liver parenchymal cells. It is raised in acute liver damage, but is also present in red cells, and cardiac and skeletal muscle and is therefore not specific to the liver. The ratio of AST to ALT is sometimes useful in differentiating between causes of liver damage:

In resource-poor settings, the AST is more frequently available than the ALT, because it is a cheaper assay.

 

Alkaline phosphatase (ALP)

Alkaline phosphatase (ALP) is an enzyme in the cells lining the biliary ducts of the liver. ALP levels in plasma will rise with large bile duct obstruction, intrahepatic cholestasis or infiltrative diseases of the liver. ALP is also present in bone and placental tissue, so it is higher in growing children (as their bones are being remodelled). The reference range is usually 30-120 U/L.

 

Total bilirubin (TBIL)

Bilirubin is a breakdown product of heme (a part of hemoglobin in red blood cells). The liver is responsible for clearing the blood of bilirubin. It does this by the following mechanism: bilirubin is taken up into hepatocytes, conjugated (modified to make it water-soluble), and secreted into the bile, which is excreted into the intestine.

Liver function tests typically measure Total bilirubin (TBIL) and Direct bilirubin (a.k.a. conjugated bilirubin, CB). Indirect bilirubin (a.k.a. unconjugated bilirubin, UCB) is obtained by subtracting direct bilirubin from total bilirubin.

Increased total bilirubin causes jaundice, and can signal a number of problems:

1. Increased bilirubin production. This can be due to a number of causes, including hemolytic anemias and internal hemorrhage.

2. Problems with the liver, which are reflected as deficiencies in bilirubin metabolism (e.g. reduced hepatocyte uptake, impaired conjugation of bilirubin, and reduced hepatocyte secretion of bilirubin). Some examples would be cirrhosis and viral hepatitis.

3. Obstruction of the bile ducts, reflected as deficiencies in bilirubin excretion. (Obstruction can be located either within the liver or outside the liver.)

The diagnosis is narrowed down further by looking at the levels of direct bilirubin. If direct (i.e. conjugated) bilirubin is normal, then the problem is an excess of unconjugated bilirubin, and the location of the problem is upstream of bilirubin excretion. Anemia, viral hepatitis, or cirrhosis can be suspected. If direct bilirubin is elevated, then the liver is conjugating bilirubin normally, but is not able to excrete it. Bile duct obstruction by gallstones or cancer should be suspected.

 

Other tests commonly requested alongside LFTs:

 

Gamma glutamyl transpeptidase (GGT)

Although reasonably specific to the liver and a more sensitive marker for cholestatic damage than ALP, Gamma glutamyl transpeptidase (GGT) may be elevated with even minor, sub-clinical levels of liver dysfunction. It can also be helpful in identifying the cause of an isolated elevation in ALP. GGT is raised in alcohol toxicity (acute and chronic).

 

5' nucleotidase (5'NTD)

5'NTD is another test specific for cholestasis or damage to the intra or extrahepatic biliary system, and in some laboratories, is used as a substitute for GGT for ascertaining whether an elevated ALP is of biliary or extra-biliary origin.

 

Coagulation tests (e.g. INR)

The liver is responsible for the production of coagulation factors. The international normalized ratio (INR) measures the speed of a particular pathway of coagulation, comparing it to normal. If the INR is increased, it means it is taking longer than usual for blood to clot. The INR will only be increased if the liver is so damaged that synthesis of vitamin K-dependent coagulation factors has been impaired: it is not a sensitive measure of liver function.

It is very important to normalize the INR before operating on people with liver problems (usually by transfusion with blood plasma containing the deficient factors) as they could bleed excessively.

 

Serum glucose (BG, Glu)

The liver's ability to produce glucose (gluconeogenesis) is usually the last function to be lost in the setting of fulminant liver failure.


 

 

SIDE EFFECTS OF ZOLOFT

During its premarketing assessment, multiple doses of ZOLOFT were administered to over 4000 adult subjects as of February 18, 2000. The conditions and duration of exposure to ZOLOFT varied greatly, and included (in overlapping categories) clinical pharmacology studies, open and double-blind studies, uncontrolled and controlled studies, inpatient and outpatient studies, fixed-dose and titration studies, and studies for multiple indications, including major depressive disorder, OCD, panic disorder, PTSD, PMDD and social anxiety disorder.

Untoward events associated with this exposure were recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of untoward events into a smaller number of standardized event categories.

In the tabulations that follow, a World Health Organization dictionary of terminology has been used to classify reported adverse events. The frequencies presented, therefore, represent the proportion of the over 4000 adult individuals exposed to multiple doses of ZOLOFT who experienced a treatment-emergent adverse event of the type cited on at least one occasion while receiving ZOLOFT. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. It is important to emphasize that events reported during therapy were not necessarily caused by it.

The prescriber should be aware that the figures in the tables and tabulations cannot be used to predict the incidence of side effects in the course of usual medical practice where patient characteristics and other factors differ from those that prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and nondrug factors to the side effect incidence rate in the population studied.

Incidence in Placebo-Controlled Trials¾Table 1 enumerates the most common treatment-emergent adverse events associated with the use of ZOLOFT (incidence of at least 5% for ZOLOFT and at least twice that for placebo within at least one of the indications) for the treatment of adult patients with major depressive disorder/other*, OCD, panic disorder, PTSD, PMDD and social anxiety disorder in placebo-controlled clinical trials. Most patients in major depressive disorder/other*, OCD, panic disorder, PTSD and social anxiety disorder studies received doses of 50 to 200 mg/day. Patients in the PMDD study with daily dosing throughout the menstrual cycle received doses of 50 to 150 mg/day, and in the PMDD study with dosing during the luteal phase of the menstrual cycle received doses of 50 to 100 mg/day. Table 2 enumerates treatment-emergent adverse events that occurred in 2% or more of adult patients treated with ZOLOFT and with incidence greater than placebo who participated in controlled clinical trials comparing ZOLOFT with placebo in the treatment of major depressive disorder/other*, OCD, panic disorder, PTSD, PMDD and social anxiety disorder. Table 2 provides combined data for the pool of studies that are provided separately by indication in Table 1.

TABLE 1

MOST COMMON TREATMENT-EMERGENT ADVERSE EVENTS: INCIDENCE IN PLACEBO-CONTROLLED CLINICAL TRIALS

 
Percentage of Patients Reporting Event
 
Major Depressive
Disorder/Other*
OCD
Panic
Disorder
PTSD
Body System/Adverse Event
ZOLOFT
(N=861)
Placebo
(N=853)
ZOLOFT
(N=533)
Placebo
(N=373)
ZOLOFT
(N=430)
Placebo
(N=275)
ZOLOFT
(N=374)
Placebo
(N=376)
Autonomic Nervous System
Disorders
               
Ejaculation Failure(1)
7
<1
17
2
19
1
11
1
Mouth Dry
16
9
14
9
15
10
11
6
Sweating Increased
8
3
6
1
5
1
4
2
Centr. & Periph. Nerv. System
Disorders
               
Somnolence
13
6
15
8
15
9
13
9
Tremor
11
3
8
1
5
1
5
1
Dizziness
12
7
17
9
10
10
8
5
General
               
Fatigue
11
8
14
10
11
6
10
5
Pain
1
2
3
1
3
3
4
6
Malaise
<1
1
1
1
7
14
10
10
Gastrointestinal Disorders
               
Abdominal Pain
2
2
5
5
6
7
6
5
Anorexia
3
2
11
2
7
2
8
2
Constipation
8
6
6
4
7
3
3
3
Diarrhea/Loose Stools
18
9
24
10
20
9
24
15
Dyspepsia
6
3
10
4
10
8
6
6
Nausea
26
12
30
11
29
18
21
11
Psychiatric Disorders
               
Agitation
6
4
6
3
6
2
5
5
Insomnia
16
9
28
12
25
18
20
11
Libido Decreased
1
<1
11
2
7
1
7
2
 
PMDD
Daily
Dosing
PMDD
Luteal Phase
Dosing(2)
   
Body System/Adverse Event
ZOLOFT
(N=121)
Placebo
(N=122)
ZOLOFT
(N=136)
Placebo
(N=127)
ZOLOFT
(N=344)
Placebo
(N=268)
   
Autonomic Nervous System
Disorders
               
Ejaculation Failure(1)
N/A
N/A
N/A
N/A
14
-
   
Mouth Dry
6
3
10
3
12
4
   
Sweating Increased
6
<1
3
0
11
2
   
Centr. & Periph. Nerv. System
Disorders
               
Somnolence
7
<1
2
0
9
6
   
Tremor
2
0
<1
<1
9
3
   
Dizziness
6
3
7
5
14
6
   
General
               
Fatigue
16
7
10
<1
12
6
   
Pain
6
<1
3
2
1
3
   
Malaise
9
5
7
5
8
3
   
Gastrointestinal Disorders
               
Abdominal Pain
7
<1
3
3
5
5
   
Anorexia
3
2
5
0
6
3
   
Constipation
2
3
1
2
5
3
   
Diarrhea/Loose Stools
13
3
13
7
21
8
   
Dyspepsia
7
2
7
3
13
5
   
Nausea
23
9
13
3
22
8
   
Psychiatric Disorders
               
Agitation
2
<1
1
0
4
2
   
Insomnia
17
11
12
10
25
10
   
Libido Decreased
11
2
4
2
9
3
   

(1)Primarily ejaculatory delay. Denominator used was for male patients only (N=271 ZOLOFT major depressive disorder/other*; N=271 placebo major depressive disorder/other*; N=296 ZOLOFT OCD; N=219 placebo OCD; N=216 ZOLOFT panic disorder; N=134 placebo panic disorder; N=130 ZOLOFT PTSD; N=149 placebo PTSD; No male patients in PMDD studies; N=205 ZOLOFT social anxiety disorder; N=153 placebo social anxiety disorder).

*Major depressive disorder and other premarketing controlled trials.

(2)The luteal phase and daily dosing PMDD trials were not designed for making direct comparisons between the two dosing regimens. Therefore, a comparison between the two dosing regimens of the PMDD trials of incidence rates shown in Table 1 should be avoided.

TABLE 2

TREATMENT-EMERGENT ADVERSE EVENTS: INCIDENCE IN PLACEBO-CONTROLLED CLINICAL TRIALS Percentage of Patients Reporting Event Major Depressive Disorder/Other*, OCD, Panic Disorder, PTSD, PMDD and Social Anxiety Disorder combined

Body System/Adverse Event**
ZOLOFT
(N=2799)
Placebo
(N=2394)
Autonomic Nervous System Disorders
   
Ejaculation Failure(1)
14
1
Mouth Dry
14
8
Sweating Increased
7
2
Centr. & Periph. Nerv. System Disorders
   
Somnolence
13
7
Dizziness
12
7
Headache
25
23
Paresthesia
2
1
Tremor
8
2
Disorders of Skin and Appendages
   
Rash
3
2
Gastrointestinal Disorders
   
Anorexia
6
2
Constipation
6
4
Diarrhea/Loose Stools
20
10
Dyspepsia
8
4
Nausea
25
11
Vomiting
4
2
General
   
Fatigue
12
7
Psychiatric Disorders
   
Agitation
5
3
Anxiety
4
3
Insomnia
21
11
Libido Decreased
6
2
Nervousness
5
4
Special Senses
   
Vision Abnormal
3
2

(1)Primarily ejaculatory delay. Denominator used was for male patients only (N=1118 ZOLOFT; N=926 placebo).

*Major depressive disorder and other premarketing controlled trials.

**Included are events reported by at least 2% of patients taking ZOLOFT except the following events, which had an incidence on placebo greater than or equal to ZOLOFT: abdominal pain, back pain, flatulence, malaise, pain, pharyngitis, respiratory disorder, upper respiratory tract infection.

Associated with Discontinuation in Placebo-Controlled Clinical Trials

Table 3 lists the adverse events associated with discontinuation of ZOLOFTÒ (sertraline hydrochloride) treatment (incidence at least twice that for placebo and at least 1% for ZOLOFT in clinical trials) in major depressive disorder/other*, OCD, panic disorder, PTSD, PMDD and social anxiety disorder.

TABLE 3

MOST COMMON ADVERSE EVENTS ASSOCIATED WITH DISCONTINUATION IN PLACEBO-CONTROLLED CLINICAL TRIALS

Adverse
Event
Major Depressive
Disorder/Other*,
OCD, Panic
Disorder, PTSD,
PMDD and Social Anxiety Disorder combined
(N=2799)
Major
Depressive
Disorder/
Other*
(N=861)
OCD
(N=533)
Panic
Disorder
(N=430)
PTSD
(N=374)
PMDD
Daily
Dosing
(N=121)
PMDD
Luteal
Phase
Dosing
(N=136)
Social
Anxiety
Disorder
(N=344)
Abdominal
Pain
¾
¾
¾
¾
¾
¾